Back

The efficacy of dual lipid-lowering therapy with ezetimibe and statin on plaque volume regression among patients following percutaneous coronary intervention: a meta-analysis

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Risk factors and prevention (2) Secondary Prevention ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Seth Azuelo

St. Luke's Medical Center, Quezon (Philippines)

5 More presentations in this session

Presentation thumbnail
Sex and age differences in the burden of cardiovascular diseases linked to an unhealthy lifestyle pattern: the ATTICA study (2002-2022)
Miss E. Damigou (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Participation in a comprehensive cardiac rehabilitation program improves mid- and long-term prognosis in survivors of acute coronary syndrome
Doctor C. Sari (Budapest, HU)
Abstract Slides Video
Presentation thumbnail
Thinning of the compact myocardial layer in excessive trabeculated individuals with genetic involvement
Doctor K. Grebur (Budapest, HU)
Abstract Slides Video
Presentation thumbnail
Physician perspectives on lipoprotein (a) testing and treatment for secondary prevention of cardiovascular disease - results from 7 countries across 6 WHO regions from the INTERASPIRE study
Doctor J. Cegla (London, GB)
Abstract Slides Video
Presentation thumbnail
Underuse of statins and antiplatelet therapy in high-risk cardiovascular patients: sex-based differences
Doctor S. Garcia-Zamora (Rosario, AR)
Abstract Slides Video

Access the full session

Session thumbnail
Risk factors and prevention (2)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
A meta analysis of effects of high-intensity statin and pcsk-9 inhibitor therapies on coronary plaque burden
thumbnail
Congress Presentation
Efficacy of combination therapy with statin and ezetimibe versus high dose statin monotherapy in secondary prevention in high-risk patients
thumbnail
Congress Presentation
High-intensity lipid-lowering therapy accelerates early plaque regression: a FLOWPROMOTE sub study.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources